[go: up one dir, main page]

EA200800064A1 - Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина - Google Patents

Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина

Info

Publication number
EA200800064A1
EA200800064A1 EA200800064A EA200800064A EA200800064A1 EA 200800064 A1 EA200800064 A1 EA 200800064A1 EA 200800064 A EA200800064 A EA 200800064A EA 200800064 A EA200800064 A EA 200800064A EA 200800064 A1 EA200800064 A1 EA 200800064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modified
immediate
memantine
freezing
granular composition
Prior art date
Application number
EA200800064A
Other languages
English (en)
Other versions
EA013474B1 (ru
Inventor
Антониа Периклоу
Ниранджан Рао
Махендра Г. Дедия
Сунил К. Растоги
Анил Чхеттри
Нарасимхан Мани
Original Assignee
Форест Лэборэтериз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форест Лэборэтериз, Инк. filed Critical Форест Лэборэтериз, Инк.
Publication of EA200800064A1 publication Critical patent/EA200800064A1/ru
Publication of EA013474B1 publication Critical patent/EA013474B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящим изобретением обеспечиваются пероральные лекарственные формы с немедленным высвобождением и модифицированным высвобождением. В частности, изобретением обеспечиваются фармацевтические лекарственные формы с модифицированным и немедленным высвобождением, содержащие мемантин, которые проявляют профиль повышенного высвобождения и обеспечивают надежное всасывание. Лекарственные формы можно использовать для лечения легкой, средней или тяжелой форм болезни Альцгеймера или невропатической боли.
EA200800064A 2005-06-16 2006-06-12 Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина EA013474B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69151205P 2005-06-16 2005-06-16
PCT/US2006/022841 WO2006138227A1 (en) 2005-06-16 2006-06-12 Modified and immediate release memantine bead formulation

Publications (2)

Publication Number Publication Date
EA200800064A1 true EA200800064A1 (ru) 2008-04-28
EA013474B1 EA013474B1 (ru) 2010-04-30

Family

ID=37025104

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800064A EA013474B1 (ru) 2005-06-16 2006-06-12 Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина

Country Status (10)

Country Link
US (6) US20070065512A1 (ru)
EP (1) EP1898890A1 (ru)
JP (1) JP2008543845A (ru)
AR (1) AR054139A1 (ru)
AU (1) AU2006259619A1 (ru)
CA (1) CA2607600A1 (ru)
EA (1) EA013474B1 (ru)
TW (1) TW200716208A (ru)
WO (1) WO2006138227A1 (ru)
ZA (1) ZA200710270B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
KR101301429B1 (ko) * 2004-11-23 2013-08-30 아다마스 파마슈티칼스, 인코포레이티드 서방성 코팅 또는 매트릭스 및 ｎｍｄａ 수용체 길항제를포함하는 조성물, 대상에 대한 상기 ｎｍｄａ 길항제의투여 방법
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
CA2654523A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
MX2009009939A (es) 2007-03-22 2010-09-24 Magceutics Inc Composiciones de magnesio y usos de la misma.
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
CA2776173A1 (en) 2009-09-30 2011-04-07 Nicholas Marini Cofactors and methods of use for individuals
US8980318B2 (en) 2010-06-24 2015-03-17 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
US8501816B2 (en) 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
CN102552218A (zh) * 2010-12-31 2012-07-11 无锡万全医药技术有限公司 一种盐酸美金刚胶囊缓释剂及其制备方法
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
WO2012110912A1 (en) * 2011-02-17 2012-08-23 Lupin Limited Sustained release composition of memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
CN103889411B (zh) 2011-07-15 2018-03-16 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
CN103181914B (zh) * 2011-12-27 2014-11-05 上海复星医药产业发展有限公司 盐酸美金刚缓释胶囊及其制备方法
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
MX2015001917A (es) 2012-08-16 2015-10-29 Teva Pharma Composiciones farmaceuticas de memantina.
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
AU2014236687A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
CN104013592B (zh) * 2014-06-10 2017-12-15 浙江京新药业股份有限公司 盐酸美金刚缓释药丸及其制备方法
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
AU2015360349B2 (en) 2014-12-12 2020-10-08 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
WO2017109547A1 (es) * 2015-12-23 2017-06-29 Laboratorios Bagó S.A. Premezcla y composición farmacéutica para la administración oral de memantina como suspensión permanente o de preparación previa a la administración al paciente y optativamente por sonda de alimentación enteral y procedimientos correspondientes
EP4556457A3 (en) 2016-06-15 2025-06-18 Ojai Energetics PBC Methods and compositions for potentiating stem cell therapies
MX2018015583A (es) 2016-06-15 2019-05-16 Ojai Energetics Pbc Metodos y composiciones para reducir el estres oxidativo.
JP6420508B2 (ja) * 2017-02-10 2018-11-07 大原薬品工業株式会社 化学的な安定性が改善された、メマンチン塩酸塩を含有する製剤
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
ES2967488T3 (es) * 2017-06-14 2024-04-30 SpecGx LLC Composiciones farmacéuticas de liberación prolongada retardada
CN108969506A (zh) * 2018-09-11 2018-12-11 山东鲁抗医药股份有限公司 一种盐酸美金刚缓释微丸及其制备方法
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
CN109172538A (zh) * 2018-10-25 2019-01-11 安徽鼎旺医药有限公司 一种盐酸美金刚速溶微丸软胶囊
JP7621940B2 (ja) 2018-11-19 2025-01-27 スパーナス ファーマシューティカルズ インコーポレイテッド 高用量の放出調節フペルジン製剤の使用
WO2020131921A1 (en) 2018-12-18 2020-06-25 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
CN113546063A (zh) * 2020-04-26 2021-10-26 江苏天士力帝益药业有限公司 一种盐酸美金刚缓释胶囊及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (ru) * 1972-04-20 1973-10-23
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2292558C (en) * 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6413556B1 (en) * 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
BR0109602A (pt) * 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
WO2002045710A1 (en) * 2000-12-07 2002-06-13 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations

Also Published As

Publication number Publication date
US20130011474A1 (en) 2013-01-10
CA2607600A1 (en) 2006-12-28
US20130302430A1 (en) 2013-11-14
AU2006259619A1 (en) 2006-12-28
EA013474B1 (ru) 2010-04-30
AR054139A1 (es) 2007-06-06
JP2008543845A (ja) 2008-12-04
ZA200710270B (en) 2008-12-31
US20150258042A1 (en) 2015-09-17
US20160346227A1 (en) 2016-12-01
US20070065512A1 (en) 2007-03-22
EP1898890A1 (en) 2008-03-19
TW200716208A (en) 2007-05-01
US20120201889A1 (en) 2012-08-09
WO2006138227A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
UA97795C2 (ru) Дейтерированные производные катехоламина и медикаменты, которые содержат упомянутые соединения
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
SG165315A1 (en) Alpha2c adrenoreceptor agonists
EP1781277A4 (en) COMBINATION PREPARATION
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
EA200702280A1 (ru) Синергические комбинации
DE602006016785D1 (de) Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
SE0203817D0 (sv) New composition
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
EA200600600A1 (ru) Применение агомелатина для приготовления лекарственных средств, предназначенных для лечения маниакально-депрессивных расстройств
RU2004101710A (ru) Препарат для лечения и профилактики послеродового эндометрита у коров и метрит-мастит-агалактин и свиноматок

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU